You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,166,771


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,166,771
Title:Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
Abstract: The present invention is directed to nucleic acid molecules and nucleic acid constructs, and other agents associated with simultaneous up- and down-regulation of expression of RNAs. Specifically it includes methods of simultaneously enhancing the expression of a first RNA at the same time as suppressing the expression of a second RNA. The present invention also specifically provides constructs capable of simultaneously enhancing the expression of a first RNA while at the same time suppressing the expression of a second RNA, methods for utilizing such agents and plants containing such agents. The present invention also provides other constructs including polycistronic constructs.
Inventor(s): Eenennaam; Alison Van (Davis, CA), Shewmaker; Christine K. (Woodland, CA)
Assignee: Monsanto Technology LLC (St. Louis, MO)
Application Number:10/668,240
Patent Claims:1. A nucleic acid molecule comprising a first nucleic acid segment comprising a polypeptide encoding sequence and a second nucleic acid segment comprising a gene suppression sequence, wherein transcription of said nucleic acid molecule in a host cell results in the simultaneous expression of a polypeptide by said polypeptide encoding sequence and suppression of a second gene in said host cell, and wherein said first nucleic acid segment and said second nucleic acid segment are operably linked to a single promoter in a polycistronic configuration.

2. The nucleic acid molecule according to claim 1, wherein said second nucleic acid segment is expressed as a dsRNA molecule.

3. The nucleic acid molecule according to claim 2, wherein said second nucleic acid segment has at least 21 contiguous nucleotides corresponding to an mRNA.

4. The nucleic acid molecule according to claim 3, wherein said second nucleic acid segment has at least 21 contiguous nucleotides corresponding to an intron from said mRNA.

5. The nucleic acid molecule according to claim 3, wherein said second nucleic acid segment has at least 21 contiguous nucleotides corresponding to an exon from said mRNA.

6. The nucleic acid molecule according to claim 3, wherein said second nucleic acid segment has at least 21 contiguous nucleotides corresponding to a 3' UTR from said mRNA.

7. The nucleic acid molecule according to claim 3, wherein said second nucleic segment acid has at least 21 contiguous nucleotides corresponding to a 5' UTR from said mRNA.

8. The nucleic acid molecule according to claim 1, wherein said suppression of a gene is suppression of an endogenous gene to said host cell.

9. A plant having in its genome a nucleic acid molecule of claim 1.

10. A method of simultaneously altering the expression of more than one RNA molecule in a plant comprising introducing into the genome of said plant a nucleic acid molecule of claim 1.

11. The method according to claim 10, wherein said second nucleic acid segment is expressed as a dsRNA molecule.

12. The method according to claim 11, wherein said second nucleic acid segment has at least 21 contiguous nucleotides corresponding to an mRNA.

13. The method according to claim 11, wherein said second nucleic acid segment has at least 21 contiguous nucleotides corresponding to an intron from said mRNA.

14. The method according to claim 11, wherein said second nucleic acid segment has at least 21 contiguous nucleotides corresponding to an exon from said mRNA.

15. The method according to claim 11, wherein said second nucleic acid segment has at least 21 contiguous nucleotides corresponding to a 3' UTR from said mRNA.

16. The method according to claim 11, wherein said second nucleic acid segment has at least 21 contiguous nucleotides corresponding to a 5' UTR from said mRNA.

17. The method according to claim 10, wherein the level of expression of at least one of said more than one RNA molecules is at least partially reduced.

18. The method according to claim 17, wherein said level of expression of at least one of said more than one RNA molecules is substantially reduced.

19. The method according claim 18, wherein the level of expression of at least one of said more than one RNA molecules is effectively eliminated.

20. A nucleic acid molecule comprising a first nucleic acid segment comprising a polypeptide encoding sequence and a second nucleic acid segment comprising a gene suppression sequence, wherein transcription of said nucleic acid molecule in a host cell results in expression of a polypeptide by said polypeptide encoding sequence and suppression of a gene in said host cell, and wherein said first nucleic acid segment and said second nucleic acid segment are operably linked to a single promoter in a polycistronic configuration, wherein said first and said second nucleic acid segments are obtained from different genes.

Details for Patent 7,166,771

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.